Similar articles for PMID: 17404325

Year	Number of Results
1976	1
1984	1
1985	1
1986	1
1987	1
1991	2
1992	1
1993	2
1995	2
1996	1
1998	2
1999	1
2000	8
2001	5
2002	2
2003	5
2004	1
2005	3
2006	2
2007	5
2008	4
2009	2
2010	4
2011	5
2012	3
2013	3
2014	1
2015	5
2016	1
2017	3
2018	7
2019	8
2020	3
2021	9
2022	2

1

Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.

Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, Bitonti A. Liu L, et al. J Immunol. 2007 Apr 15;178(8):5390-8. doi: 10.4049/jimmunol.178.8.5390. J Immunol. 2007. PMID: 17404325 Free article.

2

Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.

Yao X, Zhao J, Kong Q, Xie X, Wang J, Sun B, Xu L, Mu L, Li H. Yao X, et al. Immunol Invest. 2018 Oct;47(7):712-724. doi: 10.1080/08820139.2018.1487976. Epub 2018 Jun 26. Immunol Invest. 2018. PMID: 29944018

3

Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.

Gable KL, Guptill JT. Gable KL, et al. Front Immunol. 2020 Jan 10;10:3052. doi: 10.3389/fimmu.2019.03052. eCollection 2019. Front Immunol. 2020. PMID: 31998320 Free PMC article. Review.

4

Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.

Duan RS, Adikari SB, Huang YM, Link H, Xiao BG. Duan RS, et al. Neurobiol Dis. 2004 Jul;16(2):461-7. doi: 10.1016/j.nbd.2004.03.017. Neurobiol Dis. 2004. PMID: 15193302

5

Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.

Wu X, Tuzun E, Saini SS, Wang J, Li J, Aguilera-Aguirre L, Huda R, Christadoss P. Wu X, et al. Immunol Lett. 2015 Dec;168(2):306-12. doi: 10.1016/j.imlet.2015.10.009. Epub 2015 Oct 19. Immunol Lett. 2015. PMID: 26493475

6

Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.

Xu L, Villain M, Galin FS, Araga S, Blalock JE. Xu L, et al. Cell Immunol. 2001 Mar 15;208(2):107-14. doi: 10.1006/cimm.2001.1777. Cell Immunol. 2001. PMID: 11333143

7

Novel complement inhibitor limits severity of experimentally myasthenia gravis.

Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ. Soltys J, et al. Ann Neurol. 2009 Jan;65(1):67-75. doi: 10.1002/ana.21536. Ann Neurol. 2009. PMID: 19194881 Free PMC article.

8

Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.

Poulas K, Tsouloufis T, Tzartos SJ. Poulas K, et al. Clin Exp Immunol. 2000 May;120(2):363-8. doi: 10.1046/j.1365-2249.2000.01202.x. Clin Exp Immunol. 2000. PMID: 10792389 Free PMC article.

9

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.

Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, Atherfold P, D'Hooghe LE, Finney H, Greenslade K, Hailu H, Kevorkian L, Lightwood D, Meier C, Munro R, Qureshi O, Sarkar K, Shaw SP, Tewari R, Turner A, Tyson K, West S, Shaw S, Brennan FR. Smith B, et al. MAbs. 2018 Oct;10(7):1111-1130. doi: 10.1080/19420862.2018.1505464. Epub 2018 Sep 12. MAbs. 2018. PMID: 30130439 Free PMC article.

10

The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.

Xiao BG, Duan RS, Zhu WH, Lu CZ. Xiao BG, et al. Cell Immunol. 2006 Jun;241(2):95-101. doi: 10.1016/j.cellimm.2006.08.005. Epub 2006 Sep 26. Cell Immunol. 2006. PMID: 17005165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed